Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis

T. R. Mikuls, D. Kahn, P. C. Utrie, S. J. Miller, R. Koehnke, W. Goeckeler, K. G. Saag

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We examined the preliminary safety and efficacy of intravenous samarium-153-EDTMP (Sm-153) in the treatment of refractory rheumatoid arthritis (RA). In an open-label sequential group comparison of 0.5, 1.0, and 2.0 mCi/kg, Sm-153 was administered as a single intravenous infusion to 24 patients with refractory disease. Across treatment doses, the frequency of American College of Rheumatology (ACR) 20% responses was 25%, 29%, 25%, and 33% at 2, 4, 8, and 12 weeks, respectively. Expected significant declines in absolute neutrophil count, hemoglobin, and platelet counts were observed with nadirs seen between 2-4 weeks. Sm-153, at doses of 0.5 and 1.0mCi/kg, is well tolerated but minimally effective in the treatment of refractory RA as measured using ACR response criteria.

Original languageEnglish (US)
Pages (from-to)356-359
Number of pages4
JournalScandinavian Journal of Rheumatology
Volume30
Issue number6
DOIs
StatePublished - Dec 1 2001

Fingerprint

Rheumatoid Arthritis
Rheumatology
Platelet Count
Intravenous Infusions
Hemoglobins
Neutrophils
Therapeutics
Safety
samarium ethylenediaminetetramethylenephosphonate

Keywords

  • Radioisotope
  • Rheumatoid arthritis
  • Samarium-153-EDTMP
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Mikuls, T. R., Kahn, D., Utrie, P. C., Miller, S. J., Koehnke, R., Goeckeler, W., & Saag, K. G. (2001). Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis. Scandinavian Journal of Rheumatology, 30(6), 356-359. https://doi.org/10.1080/030097401317148561

Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis. / Mikuls, T. R.; Kahn, D.; Utrie, P. C.; Miller, S. J.; Koehnke, R.; Goeckeler, W.; Saag, K. G.

In: Scandinavian Journal of Rheumatology, Vol. 30, No. 6, 01.12.2001, p. 356-359.

Research output: Contribution to journalArticle

Mikuls, TR, Kahn, D, Utrie, PC, Miller, SJ, Koehnke, R, Goeckeler, W & Saag, KG 2001, 'Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis', Scandinavian Journal of Rheumatology, vol. 30, no. 6, pp. 356-359. https://doi.org/10.1080/030097401317148561
Mikuls, T. R. ; Kahn, D. ; Utrie, P. C. ; Miller, S. J. ; Koehnke, R. ; Goeckeler, W. ; Saag, K. G. / Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis. In: Scandinavian Journal of Rheumatology. 2001 ; Vol. 30, No. 6. pp. 356-359.
@article{7d02a3cec845499fb5ae0cd87747eade,
title = "Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis",
abstract = "We examined the preliminary safety and efficacy of intravenous samarium-153-EDTMP (Sm-153) in the treatment of refractory rheumatoid arthritis (RA). In an open-label sequential group comparison of 0.5, 1.0, and 2.0 mCi/kg, Sm-153 was administered as a single intravenous infusion to 24 patients with refractory disease. Across treatment doses, the frequency of American College of Rheumatology (ACR) 20{\%} responses was 25{\%}, 29{\%}, 25{\%}, and 33{\%} at 2, 4, 8, and 12 weeks, respectively. Expected significant declines in absolute neutrophil count, hemoglobin, and platelet counts were observed with nadirs seen between 2-4 weeks. Sm-153, at doses of 0.5 and 1.0mCi/kg, is well tolerated but minimally effective in the treatment of refractory RA as measured using ACR response criteria.",
keywords = "Radioisotope, Rheumatoid arthritis, Samarium-153-EDTMP, Treatment",
author = "Mikuls, {T. R.} and D. Kahn and Utrie, {P. C.} and Miller, {S. J.} and R. Koehnke and W. Goeckeler and Saag, {K. G.}",
year = "2001",
month = "12",
day = "1",
doi = "10.1080/030097401317148561",
language = "English (US)",
volume = "30",
pages = "356--359",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Samarium-153-EDTMP in the treatment of refractory rheumatoid arthritis

AU - Mikuls, T. R.

AU - Kahn, D.

AU - Utrie, P. C.

AU - Miller, S. J.

AU - Koehnke, R.

AU - Goeckeler, W.

AU - Saag, K. G.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - We examined the preliminary safety and efficacy of intravenous samarium-153-EDTMP (Sm-153) in the treatment of refractory rheumatoid arthritis (RA). In an open-label sequential group comparison of 0.5, 1.0, and 2.0 mCi/kg, Sm-153 was administered as a single intravenous infusion to 24 patients with refractory disease. Across treatment doses, the frequency of American College of Rheumatology (ACR) 20% responses was 25%, 29%, 25%, and 33% at 2, 4, 8, and 12 weeks, respectively. Expected significant declines in absolute neutrophil count, hemoglobin, and platelet counts were observed with nadirs seen between 2-4 weeks. Sm-153, at doses of 0.5 and 1.0mCi/kg, is well tolerated but minimally effective in the treatment of refractory RA as measured using ACR response criteria.

AB - We examined the preliminary safety and efficacy of intravenous samarium-153-EDTMP (Sm-153) in the treatment of refractory rheumatoid arthritis (RA). In an open-label sequential group comparison of 0.5, 1.0, and 2.0 mCi/kg, Sm-153 was administered as a single intravenous infusion to 24 patients with refractory disease. Across treatment doses, the frequency of American College of Rheumatology (ACR) 20% responses was 25%, 29%, 25%, and 33% at 2, 4, 8, and 12 weeks, respectively. Expected significant declines in absolute neutrophil count, hemoglobin, and platelet counts were observed with nadirs seen between 2-4 weeks. Sm-153, at doses of 0.5 and 1.0mCi/kg, is well tolerated but minimally effective in the treatment of refractory RA as measured using ACR response criteria.

KW - Radioisotope

KW - Rheumatoid arthritis

KW - Samarium-153-EDTMP

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0035665768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035665768&partnerID=8YFLogxK

U2 - 10.1080/030097401317148561

DO - 10.1080/030097401317148561

M3 - Article

C2 - 11846055

AN - SCOPUS:0035665768

VL - 30

SP - 356

EP - 359

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 6

ER -